Adocia : 2024, un exercice potentiellement transformant pour Adocia
>Un cash burn opérationnel en net recul - Adocia a publié hier soir ses chiffres au titre de l’exercice 2023. Les produits opérationnels sur la période ressortent à 6 M€ (vs 17.3 M€ en 2022 dont un milestone de 4.8 M€ reçu dans le cadre de son partenariat en Chine). Les charges opérationnelles courantes sont en baisse de 31% à 20.3 M€ sous l’effet du recul des charges R&D à 14.8 M€ (vs 25.9 M€ en 2022). Il en résulte une perte courante de -14.2 M€ (contre -12.9 M€ un ...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.